GlassScriptPhysician profile
Mary Levine
NPI 1639326671
$3,262.14
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $632 · 2022: $1,307 · 2023: $974 · 2024: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,112.45 | 2021-2024 | |
| Axsome Therapeutics, INC. | $347.38 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $243.63 | 2021-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $207.88 | 2021-2022 | |
| Alkermes, INC. | $202.48 | 2021-2024 | Aristada, Lybalvi |
| Almatica Pharma LLC | $191.98 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.12 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $167.73 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $123.97 | 2021-2024 | Abilify Asimtufii, Rexulti |
| Idorsia Pharmaceuticals US INC | $105.15 | 2022-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $85.35 | 2021-2023 | Ingrezza |
| Lundbeck LLC | $82.50 | 2021-2024 | Rexulti |
| Bausch Health US, LLC | $82.41 | 2021-2023 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $51.97 | 2022 | |
| Indivior INC. | $27.43 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $15.66 | 2023 | Adzenys Xr-Odt |
| Acadia Pharmaceuticals INC | $14.67 | 2021 | |
| Alfasigma USA, INC. | $14.00 | 2021 | |
| Vanda Pharmaceuticals INC. | $13.38 | 2023 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.